Biotech Values

[DewDiligence]

EXAS—Colon Cancer Alliance blasts USPSTF’s evaluation of Cologuard:

http://www.prnewswire.com/news-releases/colon-cancer-alliance-us-preventive-services-task-force-recommendations-300157279.html

My contemporaneous (2013) view on this matter (#msg-86983487) was that Cologuard's 87% specificity could be a problem vis-à-vis commercial uptake, and that turned out to be a pretty good call.

However, USPSTF has gone too far, IMO, by improperly defining the test's specificity (#msg-117515504) and failing to take into account the test’s 3-year interval, thereby relegating Cologuard to “alternative” rather than “recommended” status. Thus, I find the arguments in the CCA’s PR (linked above) to be valid.